(trospium chloride + xanomeline tartrate)

all catalysts(0)

nothing on the calendar yet

News(10)

• As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
  Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…
  biospace · 1d ago
• As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
  While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
  biospace · 7d ago
• An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
  In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
  biopharma_dive · 8d ago
• Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
  Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
  biopharma_dive · 11d ago
• BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
  Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…
  biospace · 12d ago
• Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
  Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.
  fiercebiotech · 12d ago
• MapLight CEO on what investors missed in the biotech’s schizophrenia data
  Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."
  biopharma_dive · 12d ago
• MapLight dives despite positive data for schizophrenia drug
  Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
  biopharma_dive · 15d ago
• MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
  While MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb's Cobenfy is likely to hold its market share.
  biospace · 15d ago
• MapLight shares sink on mixed phase 2 schizophrenia readout
  MapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.
  fiercebiotech · 15d ago